In The News

    UTEP Logo

    UTEP's First Biotechnology Spin-Off Company

    The University of Texas at EI Paso Announces First Biotech Spin-off Worldwide Exclusive Licensing Agreement with SeneXta Therapeutics SA for Novel Compound for Treatment of Alzheimer's Disease and Stroke

     

    EL PASO, TX-University of Texas at EI Paso (UTEP) officials are proudSenexta Logo to announce the spin-off of SeneXta Therapeutics SA, a Swiss based biopharmaceutical company focused on the research and development of therapies for neurodegenerative disorders including Alzheimer’s disease.

    The University of Texas at EI Paso and SeneXta Therapeutics SA has signed a worldwide exclusive licensing agreement to develop and market a promising drug therapy for Alzheimer’s disease invented by distinguished UTEP Professor

    Dr. Moss
    Dr. Donald Moss

    Donald E. Moss, Ph.D., of the Department of Psychology.

    "We are excited to sign this agreement with UTEP and look forward to establishing a solid and long-lasting collaboration with the University. MSF holds great potential in treating patients with Alzheimer's disease and stroke, said Enrico Braglia, CEO and founder of SeneXta.

    Co-founder and Chief operating Officer Federica Pericle, Ph.D., will be UTEP's liaison for SeneXta in EI Paso. Dr. Pericle is the associate vice president for biotechnology in UTEP's Office of Research hand Sponsored Projects.

    SeneXta is the first biotechnology company to be spun off from UTEP intellectual property. The details of the new company were presented this week during an event on campus that included a tour of UTEP's bioscience research facilities.

    UTEP President Diana Natalicio said the SeneXta spin-off is an example of how UTEP is building on the university's traditional research strength in science and engineering and growing expertise in the life sciences.

    "UTEP is developing a strong capacity in translational medicine: biotechnology and pharmaceutical research discoveries that can move from the laboratory into clinical practice to diagnose and treat patients, Natalicio said. "Alzheimer's occurs at a disproportionate rate among Hispanics so it is especially gratifying that the research is to fight this.”

    Event Related Links
    EI Paso Times
    Alzheimer's treatment: UTEP professor forges marketing deal
    EI Paso Inc.
    Drug venture is UTEP’s first biotech spinoff
    http://www.senexta.com/Brochure-Senexta-v4.pdf


 

Top Stories